344-70-7

Usage

Uses

Used in Organic Synthesis:
4-(acetylamino)-2-fluorobenzenesulfonyl chloride is used as a reagent for the synthesis of various organic compounds due to its ability to react with nucleophiles such as amines and alcohols, facilitating the formation of amides and esters.
Used in Pharmaceutical Research and Drug Development:
In the pharmaceutical industry, 4-(acetylamino)-2-fluorobenzenesulfonyl chloride is used as a chemical probe for enzyme inhibition and protein modification. Its potential in this field is attributed to its capacity to interact with biological targets, offering a pathway for the development of new drugs.
Used in Biomolecular Modification and Labeling:
4-(acetylamino)-2-fluorobenzenesulfonyl chloride is utilized as a modifier and label for biomolecules owing to its structural relation to sulfonyl chlorides and the presence of a fluoro substituent, which enhances its reactivity and selectivity in biological systems.

Upstream product

• 351-28-0 N-(3-fluorophenyl)acetamide 
• 372-19-0 meta-fluoroaniline 

Downstream Products

• 1331890-91-5 N-(3-fluoro-4-(N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)sulfamoyl)phenyl)acetamide 
• 1308254-63-8 4-amino-2-fluoro-N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)benzenesulfonamide 
• 654063-26-0 N-(3-fluoro-4-methylsulfamoylphenyl)acetamide 

Relevant academic research and scientific papers

Chagas Disease Drug Discovery: Multiparametric Lead Optimization against Trypanosoma cruzi in Acylaminobenzothiazole Series

Acylaminobenzothiazole hits were identified as potential inhibitors of Trypanosoma cruzi replication, a parasite responsible for Chagas disease. We selected compound 1 for lead optimization, aiming to improve in parallel its anti-T. cruzi activity (IC50 = 0.63 μM) and its human metabolic stability (human clearance = 9.57 mL/min/g). A total of 39 analogues of 1 were synthesized and tested in vitro. We established a multiparametric structure-activity relationship, allowing optimization of antiparasite activity, physicochemical parameters, and ADME properties. We identified compound 50 as an advanced lead with an improved anti-T. cruzi activity in vitro (IC50 = 0.079 μM) and an enhanced metabolic stability (human clearance = 0.41 mL/min/g) and opportunity for the oral route of administration. After tolerability assessment, 50 demonstrated a promising in vivo efficacy.

BORON-CONTAINING SMALL MOLECULES

This invention relates to 6-substituted benzoxaborole compounds of the following formula and their use for treating bacterial infections.